title: Combination therapy for obesity and metabolic disease.
abstract: OBJECTIVE
  There is a growing interest in developing combination therapies for treatment and management of obesity and related metabolic diseases.
  
  
  RESULTS
  Emerging data from recently completed and ongoing randomized clinical trials suggest that certain combination-drug therapies in development have greater efficacy than currently available single-drug therapies in terms of achieved weight loss and reduction in risk factors.
  
  
  CONCLUSIONS
  Combination-drug therapy may have a role in the treatment of obesity and related diseases as well as for prevention of risk factors. As we await safety data from studies with larger samples, the demonstrated efficacy of some of the combination drug therapies in late-stage development appears to be robust and clinically meaningful.
authors.affiliation: Obesity Clinical Trials Programme, Duke University Medical Centre, Durham, North Carolina 27710, USA.
authors.forename: Kishore M
authors.initials: KM
authors.lastname: Gadde
authors.forename: David B
authors.initials: DB
authors.lastname: Allison
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D008659:Metabolic Diseases / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D019440:Anti-Obesity Agents; D004338:Drug Combinations; D007004:Hypoglycemic Agents